PDS Biotechnology (NASDAQ:PDSB) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a report released on Friday morning.

Several other equities research analysts have also recently commented on PDSB. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, October 24th. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, PDS Biotechnology currently has a consensus rating of “Buy” and an average price target of $14.25.

PDS Biotechnology Price Performance

PDSB stock traded up $0.01 during trading on Friday, hitting $3.20. The company had a trading volume of 250,900 shares, compared to its average volume of 610,675. The firm has a market capitalization of $117.82 million, a price-to-earnings ratio of -2.62 and a beta of 1.93. The business has a 50 day moving average of $3.24 and a 200 day moving average of $3.27. PDS Biotechnology has a fifty-two week low of $2.53 and a fifty-two week high of $6.85. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company posted ($0.37) earnings per share. As a group, research analysts predict that PDS Biotechnology will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On PDS Biotechnology

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of PDS Biotechnology by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the period. Inspirion Wealth Advisors LLC increased its holdings in shares of PDS Biotechnology by 1.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after purchasing an additional 4,917 shares during the period. Blair William & Co. IL increased its holdings in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at about $146,000. Finally, Squarepoint Ops LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter valued at approximately $120,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.